As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, specialized models, and integration into diagnostic workflows.
According to a recent McKinsey & Company report, the true competitive moat could be found around securing proprietary data and embedding your software deeply into daily workflows. Tempus AI is a perfect example of this in action.
Key Takeaways
- Pure software companies face systemic access bottlenecks due to strict regulations and proprietary clinical data silos.
- Tempus AI (TEM) sits at the intersection of AI infrastructure and clinical diagnostics, leveraging a vast proprietary multimodal database.
- The company is a holding in both the ROBO Global Artificial Intelligence ETF (THNQ ) and the ROBO Global Healthcare Technology and Innovation ETF (HTEC ).
The AI Data Moat Bottleneck
Physical laboratory hardware creates a major bottleneck in AI-driven drug discovery. However, a second constraint lies ahead: Secure access to proprietary patient data.
Compute alone cannot solve the challenge of obtaining, connecting, and maintaining usable clinical data. Doing so requires healthcare relationships, appropriate data rights, and substantial integration and curation. Tempus AI (TEM) is an example of this integrated approach.
Why Static Datasets Aren't Enough
Tempus combines clinical laboratory operations with healthcare-provider integrations to assemble and curate multimodal datasets, including de-identified clinical and genomic records. Connecting clinical history with molecular testing can help contextualize diagnostic findings and improve patient care.
Tempus designed its business around integrated data pipelines with healthcare partners from the beginning. While anyone with enough capital can buy a static dataset once, setting up live, compliant systems that pull updated clinical data continuously creates a moat that any single company would struggle to replicate.
This setup mirrors two key moats outlined by McKinsey: Privileged data and deep workflow embeddedness. Deep integrations can create switching costs through the work required to rebuild data connections and clinical workflows.
Bridging Tech Infrastructure & Precision Healthcare
Because Tempus combines tech infrastructure with clinical execution, it plays a dual role across thematic strategies.
The stock has emerged as a top holding in the ROBO Global Artificial Intelligence ETF (THNQ ), sitting alongside cloud infrastructure giants and chipmakers. At the same time, its clinical decision-support tools and diagnostic research make it a natural fit in the ROBO Global Healthcare Technology and Innovation ETF (HTEC ).
Read more: THNQ Hits Milestone Highs on Record Outperformance Over QQQ
Looking for regular updates? Subscribe here for weekly insights on robotics, AI, and healthcare technology, delivered straight to your inbox.
For more news, information, and analysis, visit the Artificial Intelligence Content Hub.
vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for HTEC and THNQ, for which it receives an index licensing fee. However, HTEC and THNQ are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC and THNQ.
